Alembic Pharmaceuticals Inkomsten in het verleden
Verleden criteriumcontroles 4/6
De winst van Alembic Pharmaceuticals is gedaald met een gemiddeld jaarlijks percentage van -13.8%, terwijl de winst van de Pharmaceuticals -industrie jaarlijks groeide met 13.4%. De inkomsten zijn groeide met een gemiddeld percentage van 7.3% per jaar. Het rendement op het eigen vermogen Alembic Pharmaceuticals bedraagt 13.1% en de nettomarge bedraagt 10%.
Belangrijke informatie
-13.8%
Groei van de winst
-14.8%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 17.5% |
| Inkomstengroei | 7.3% |
| Rendement op eigen vermogen | 13.1% |
| Nettomarge | 10.0% |
| Volgende winstupdate | 07 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price
Sep 25
Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?
Sep 03Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 13Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher
Jul 20Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly
Jun 03Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?
May 11Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 08Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%
Jan 21Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Jan 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly
Sep 27Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jun 09A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Apr 13Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Feb 22Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jan 04We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now
Nov 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden
Aug 10Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Jul 20We Think Alembic Pharmaceuticals (NSE:APLLTD) Is Taking Some Risk With Its Debt
May 05Opbrengsten en kosten
Hoe Alembic Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 63,042 | 6,299 | 14,808 | 0 |
| 31 Mar 24 | 62,286 | 6,158 | 14,492 | 0 |
| 31 Dec 23 | 61,181 | 5,902 | 13,484 | 0 |
| 30 Sep 23 | 59,966 | 5,317 | 12,904 | 0 |
| 30 Jun 23 | 58,766 | 5,285 | 12,332 | 0 |
| 31 Mar 23 | 56,526 | 3,420 | 11,755 | 0 |
| 31 Dec 22 | 56,619 | 2,113 | 11,540 | 0 |
| 30 Sep 22 | 54,246 | 2,662 | 11,354 | 0 |
| 30 Jun 22 | 52,419 | 3,153 | 11,335 | 0 |
| 31 Mar 22 | 53,058 | 5,209 | 11,382 | 0 |
| 31 Dec 21 | 51,704 | 7,609 | 10,951 | 0 |
| 30 Sep 21 | 52,131 | 8,771 | 10,848 | 0 |
| 30 Jun 21 | 53,778 | 10,412 | 10,678 | 0 |
| 31 Mar 21 | 53,931 | 11,465 | 10,514 | 0 |
| 31 Dec 20 | 53,196 | 11,521 | 10,639 | 0 |
| 30 Sep 20 | 52,144 | 10,937 | 10,283 | 0 |
| 30 Jun 20 | 49,982 | 10,066 | 9,699 | 0 |
| 31 Mar 20 | 46,058 | 8,288 | 9,094 | 0 |
| 31 Dec 19 | 43,259 | 7,282 | 8,941 | 0 |
| 30 Sep 19 | 41,349 | 6,638 | 8,656 | 0 |
| 30 Jun 19 | 40,211 | 6,176 | 8,305 | 0 |
| 31 Mar 19 | 39,347 | 5,844 | 7,773 | 0 |
| 31 Dec 18 | 38,604 | 5,542 | 7,176 | 0 |
| 30 Sep 18 | 36,823 | 5,149 | 6,667 | 0 |
| 30 Jun 18 | 33,445 | 4,364 | 6,436 | 0 |
| 31 Mar 18 | 31,302 | 4,126 | 6,372 | 0 |
| 31 Dec 17 | 29,894 | 4,119 | 6,188 | 0 |
| 30 Sep 17 | 29,264 | 3,678 | 6,207 | 0 |
| 30 Jun 17 | 30,165 | 3,661 | 5,833 | 0 |
| 31 Mar 17 | 31,052 | 4,032 | 5,737 | 0 |
| 31 Dec 16 | 30,130 | 3,999 | 4,774 | 4,159 |
| 30 Sep 16 | 31,584 | 5,828 | 4,644 | 3,693 |
| 30 Jun 16 | 32,942 | 7,515 | 4,648 | 3,386 |
| 31 Mar 16 | 31,232 | 7,200 | 4,867 | 0 |
| 31 Dec 15 | 30,185 | 6,986 | 7,878 | 2,265 |
| 30 Sep 15 | 26,086 | 4,998 | 7,499 | 1,869 |
| 30 Jun 15 | 21,469 | 2,881 | 7,128 | 1,400 |
| 31 Mar 15 | 20,579 | 2,829 | 3,159 | 1,216 |
| 31 Dec 14 | 20,167 | 2,739 | 6,470 | 1,223 |
| 30 Sep 14 | 19,906 | 2,692 | 6,184 | 1,208 |
| 30 Jun 14 | 19,303 | 2,535 | 5,781 | 1,236 |
| 31 Mar 14 | 18,642 | 2,355 | 5,498 | 1,164 |
| 31 Dec 13 | 17,770 | 2,179 | 4,689 | 1,072 |
Kwaliteitswinsten: APLLTD heeft hoge kwaliteitsinkomsten.
Groeiende winstmarge: De huidige netto winstmarges (10%) APLLTD } zijn hoger dan vorig jaar (9%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van APLLTD is de afgelopen 5 jaar met 13.8% per jaar gedaald.
Versnelling van de groei: De winstgroei van APLLTD over het afgelopen jaar ( 19.2% ) overtreft het 5-jarig gemiddelde ( -13.8% per jaar).
Winst versus industrie: De winstgroei APLLTD over het afgelopen jaar ( 19.2% ) overtrof de Pharmaceuticals -sector 19.1%.
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 13.1% ) van APLLTD wordt als laag beschouwd.